Search results
Results from the WOW.Com Content Network
Endo Pharmaceuticals (ENDP) agreed to buy generics company Qualitest Pharmaceuticals for $1.2 billion cash. Qualitest is the sixth-largest U.S. generics company as measured by prescriptions filled.
2010: Endo acquired generic manufacturer Qualitest Pharmaceuticals for $1.2 billion [8] 2011: Endo acquired medical device manufacturer American Medical Systems for more than $2 billion [18] [19] [7] 2013: Endo agreed to purchase Paladin Labs Inc for about $1.6 billion to gain access to the Canadian market as well as expand into emerging markets.
Actavis Generics [1] (formerly known as Watson Pharmaceuticals and Actavis plc, prior to the acquisition of Irish-based Allergan, Inc.) is a global pharmaceutical company focused on acquiring, developing, manufacturing and marketing branded pharmaceuticals, generic and over-the-counter medicines, and biologic products.
Mylan N.V. was a global generic and specialty pharmaceuticals company. In November 2020, Mylan merged with Upjohn, Pfizer's off-patent medicine division, to form Viatris. [2] ...
NPS Pharmaceuticals is a biopharmaceutical company focused on bringing orphan products to patients with rare disorders and few, if any, therapeutic options. NPS is advancing two late-stage ...
Stock indexes drifted to a mixed finish on Wall Street as some heavyweight technology and communications sector stocks offset gains elsewhere in the market. The S&P 500 slipped less than 0.1% ...
Bausch Health Companies Inc. (formerly Valeant Pharmaceuticals International, Inc.) is an American-Canadian multinational specialty pharmaceutical company based in Laval, Quebec, Canada. It develops, manufactures and markets pharmaceutical products and branded generic drugs , primarily for skin diseases , gastrointestinal disorders , eye health ...
Founded in 1919 as a maker of digitalis drugs, [3] Upsher-Smith has traditionally focused on the manufacture of generic medications.. In 2017, after owning it for 47 years, the Evenstad family decided to sell most of the firm, the generics business, to Sawai Group Holdings Co., Ltd. [], a large publicly traded generics company in Japan that had been seeking entry into the U.S. market. [4]